These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11837705)

  • 21. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
    Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
    Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
    Jain S; Saraf S
    J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and pharmacodynamics of IONIS-GCGR
    Luu KT; Morgan ES; Bhanot S; Geary R; Smith A; Bethune C; Watts L; Henry S; Wang Y
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):179-191. PubMed ID: 28132162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
    Meneilly GS
    Diabetes Technol Ther; 2011 Jan; 13(1):63-5. PubMed ID: 21175273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis.
    Gobburu JV; Chen EP
    J Pharm Sci; 1996 May; 85(5):505-10. PubMed ID: 8742942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs.
    He W; Wu M; Huang S; Yin L
    Int J Pharm; 2015 Jan; 478(1):297-307. PubMed ID: 25434592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
    Frey N; Laveille C; Paraire M; Francillard M; Holford NH; Jochemsen R
    Br J Clin Pharmacol; 2003 Feb; 55(2):147-57. PubMed ID: 12580986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
    Niemi M; Kajosaari LI; Neuvonen M; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):441-7. PubMed ID: 15025742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
    Scheen AJ
    Rev Med Liege; 2001 Jun; 56(6):456-9. PubMed ID: 11496727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
    Guay DR
    Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies.
    Tavakoli N; Minaiyan M; Tabbakhian M; Pendar Y
    J Microencapsul; 2014; 31(6):529-34. PubMed ID: 24697183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-site absorption model fits to pharmacokinetic data of repaglinide in man.
    Liu XD; Ji HF; Xie L; Yan MQ; Zhang L; Huang X
    Eur J Drug Metab Pharmacokinet; 2000; 25(2):115-9. PubMed ID: 11112092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.